MRICCV and MTR were both lowered in patients with higher NfH, supporting earlier associations of NfH with clinical measures and connecting progressive brain atrophy in SPMS to NfH release and a reduction in cerebral volumes (MRICCV) and global disease burden (MTR). This evidence concerns the gene NEFH and secondary progressive multiple sclerosis.